Featured Research

from universities, journals, and other organizations

Researchers Design New Way To Squelch Errant Enzymes

Date:
January 22, 2001
Source:
Johns Hopkins Medical Institutions
Summary:
Scientists at Johns Hopkins, New York University and Mount Sinai School of Medicine in New York have found a way to block the action of specific enzymes with a pivotal role in triggering cancers, hardening of the arteries and certain autoimmune diseases.

Scientists at Johns Hopkins, New York University and Mount Sinai School of Medicine in New York have found a way to block the action of specific enzymes with a pivotal role in triggering cancers, hardening of the arteries and certain autoimmune diseases.

Their research, described in this month's Nature Structural Biology, explains how a blockading molecule, called a bisubstrate analog, effectively prevents protein kinase enzymes from docking with other molecules in the body — in short, from working. "The bisubstrate analogs are extremely potent in inhibiting reactions," says Philip A. Cole, M.D., Ph.D., who led the research.

The researchers designed the bisubstrate analog using an improved understanding of how protein kinases normally work at the molecular level. They liken their work to the science that produced the protease inhibiting drugs that tipped the disease scales from fatal to chronic for many AIDS sufferers. "We don't have a drug for patients yet, but this is still a real advance in the field," Cole adds.

Protein kinases are widespread in the body. "About 2 percent of our genes code for protein kinases," says Cole. The enzymes help ferry a small, reactive cluster of atoms containing phosphorus — called a phosphoryl group — to cell proteins. Once thought to be a mere housekeeping procedure, this transfer, researchers now know, is crucial to cells. Once a protein gains a phosphoryl group, Cole says, the protein changes, becoming a key player in cell reactions that prompt growth and reproduction.

"Our work may be particularly helpful in developing therapies for cancers," says Cole, "which can stem from mutations in genes that regulate kinases." Experiments show that too much of a particular kinase can lead to tumors, and that autoimmune diseases such as arthritis and other inflammatory conditions probably involve kinases that are too efficient or overactive. "Finding a way to inhibit them is probably a very good idea," Cole adds.

Unlike other approaches to block protein kinases, the researchers say, the new technique works both on the molecules that donate the phosphoryl groups and on the protein molecules that accept them. Their bisubstrate analog simultaneously attaches to both molecules, crowding out protein kinases.

Most important, Cole says, is that their approach targets specific protein kinases. "There are probably several thousand different kinases with roles in different disease pathways. The biggest problem has been singling out specific ones to inhibit," he says. Minor tinkering with bisubstrate analogs may produce a wide variety of the molecular red herrings, each designed to counteract a specific protein kinase.

Cole's team now plans versions of the analogs that can persist long enough in the human body to be useful therapy. Grants from the National Institutes of Health and the Burroughs Wellcome Fund supported the research. The researchers have applied for a patent on the bisubstrate analog.

Other researchers are Keykavous Parang, Ph.D., recently at Johns Hopkins but now at the University of Rhode Island, Jeffrey H. Till and Stevan R. Hubbard with the New York University School of Medicine, and Ararat J. Ablooglu and Ronald A. Kohanski at the Mount Sinai School of Medicine in New York city.


Story Source:

The above story is based on materials provided by Johns Hopkins Medical Institutions. Note: Materials may be edited for content and length.


Cite This Page:

Johns Hopkins Medical Institutions. "Researchers Design New Way To Squelch Errant Enzymes." ScienceDaily. ScienceDaily, 22 January 2001. <www.sciencedaily.com/releases/2001/01/010118065110.htm>.
Johns Hopkins Medical Institutions. (2001, January 22). Researchers Design New Way To Squelch Errant Enzymes. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2001/01/010118065110.htm
Johns Hopkins Medical Institutions. "Researchers Design New Way To Squelch Errant Enzymes." ScienceDaily. www.sciencedaily.com/releases/2001/01/010118065110.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins